Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Fragile X syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms CONNECT-FX
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 09 Jul 2018 According to a Zynerba Pharmaceuticals media release, based on discussions with the U.S. FDA, the Company will anchor the CGI-I scale to behavioral symptoms of FXS.
    • 09 Jul 2018 According to a Zynerba Pharmaceuticals media release, top line results are expected in the second half of 2019.
    • 09 Jul 2018 Status changed from not yet recruiting to recruiting, as reported in a Zynerba Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top